StockNews.com Initiates Coverage on NeuroMetrix (NASDAQ:NURO)

StockNews.com assumed coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report released on Thursday. The firm issued a sell rating on the medical device company’s stock.

NeuroMetrix Trading Down 0.7 %

NURO opened at $4.27 on Thursday. NeuroMetrix has a twelve month low of $2.66 and a twelve month high of $4.73. The firm has a market cap of $8.71 million, a price-to-earnings ratio of -0.93 and a beta of 2.29. The company has a fifty day simple moving average of $4.08 and a 200 day simple moving average of $3.83.

NeuroMetrix (NASDAQ:NURO) last released its quarterly earnings results on Tuesday, November 5th. The medical device company reported ($0.75) EPS for the quarter. NeuroMetrix had a negative return on equity of 42.56% and a negative net margin of 203.71%. The business had revenue of $0.59 million during the quarter. During the same quarter last year, the business posted ($1.66) EPS.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.